Logo
Clinicogenomics

Guide Early Discovery for Clinical Development

Enrich real-world oncology patient data with comprehensive genomic profiling information to discover hidden patterns and inform early-stage drug discovery research.

Group 48
Use Cases

Future-Plan for Clinical Research and Development

Clinicogenomics is an optional add-on designed to enrich our robust oncology patient data with genomic markers to help generate insights about new research and development opportunities.

Genomic Data Includes:

Group 213

COTA by the Numbers

2.1M+ Cancer Patient Lives

50/50 Academic vs. Community Treatment Setting

3 Approvals Supported

9 Hematology and Solid Tumor Diagnoses

5-Year Average Follow-up

2X Higher Inclusion Percentage in ECA vs. Competitor

Group 203
Additional Support

Get the Most of Your Clinicogenomics Data with Real-World Insights and Support

Real-World Support gives you access to industry veterans who can help you structure study designs, provide guidance on protocol and analysis,
make recommendations for regulatory submission packets, review research and manuscripts, and more to ensure your research achieves the highest quality standards.

Resources

Fueling the Future of Cancer Research

Explore our collection of clinical research, recent press, podcasts, and more.

Exploring standards of care in real-world settings with RWD

Real-world data (RWD) can help to illuminate patterns in therapy selection and the correlation to outcomes, giving oncologists and researchers...

From Data to Discovery: How AI Is Accelerating Progress in Oncology

the latest wave of data, technology, and artificial intelligence (AI) advances are challenging views, empowering individuals across life sciences functions...

How COTA & Komodo Health Combine Real-World Datasets for Better Patient Insights

Komodo Health and COTA teamed up to link COTA’s high-quality oncology data with Komodo’s vast Healthcare MapTM...

Find Your Next Breakthrough

Discover the power of real world cancer data to help you understand patient journeys across the oncology spectrum and inform research directions.
Group 11